Symbols / TGTX
TGTX Chart
About
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. The company was incorporated in 1993 and is based in Morrisville, North Carolina.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 4.84B |
| Enterprise Value | 4.59B | Income | 447.47M | Sales | 531.90M |
| Book/sh | 4.26 | Cash/sh | 0.90 | Dividend Yield | — |
| Payout | 0.00% | Employees | 374 | IPO | — |
| P/E | 11.01 | Forward P/E | 18.83 | PEG | — |
| P/S | 9.11 | P/B | 7.17 | P/C | — |
| EV/EBITDA | 44.66 | EV/Sales | 8.63 | Quick Ratio | 2.53 |
| Current Ratio | 3.83 | Debt/Eq | 41.92 | LT Debt/Eq | — |
| EPS (ttm) | 2.77 | EPS next Y | 1.62 | EPS Growth | 120.50% |
| Revenue Growth | 92.80% | Earnings | 2026-02-26 | ROA | 7.98% |
| ROE | 111.96% | ROIC | — | Gross Margin | 85.34% |
| Oper. Margin | 18.16% | Profit Margin | 84.13% | Shs Outstand | 158.76M |
| Shs Float | 139.47M | Short Float | 23.84% | Short Ratio | 12.03 |
| Short Interest | — | 52W High | 46.48 | 52W Low | 25.28 |
| Beta | 1.87 | Avg Volume | 1.80M | Volume | 1.26M |
| Target Price | $44.43 | Recom | Buy | Prev Close | $30.57 |
| Price | $30.51 | Change | -0.20% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$44.43
Mean price target
2. Current target
$30.51
Latest analyst target
3. DCF / Fair value
$-10.73
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$30.51
Low
$15.00
High
$60.00
Mean
$44.43
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-02 | main | JP Morgan | Overweight → Overweight | $46 |
| 2026-01-15 | main | Goldman Sachs | Neutral → Neutral | $39 |
| 2025-11-03 | main | JP Morgan | Overweight → Overweight | $49 |
| 2025-09-17 | main | B. Riley Securities | Buy → Buy | $55 |
| 2025-03-04 | reit | HC Wainwright & Co. | Buy → Buy | $55 |
| 2025-01-15 | reit | HC Wainwright & Co. | Buy → Buy | $55 |
| 2024-11-25 | main | JP Morgan | Overweight → Overweight | $43 |
| 2024-11-05 | main | HC Wainwright & Co. | Buy → Buy | $55 |
| 2024-11-05 | main | Goldman Sachs | Neutral → Neutral | $22 |
| 2024-10-29 | init | TD Cowen | — → Buy | $50 |
| 2024-09-18 | reit | HC Wainwright & Co. | Buy → Buy | $49 |
| 2024-08-07 | main | B. Riley Securities | Buy → Buy | $34 |
| 2024-08-07 | main | Goldman Sachs | Neutral → Neutral | $20 |
| 2024-08-06 | reit | HC Wainwright & Co. | Buy → Buy | $49 |
| 2024-05-02 | main | HC Wainwright & Co. | Buy → Buy | $49 |
| 2024-05-02 | main | Ladenburg Thalmann | Buy → Buy | $40 |
| 2024-04-18 | reit | HC Wainwright & Co. | Buy → Buy | $45 |
| 2024-04-18 | reit | JP Morgan | Overweight → Overweight | $25 |
| 2024-04-18 | reit | Ladenburg Thalmann | Buy → Buy | $39 |
| 2024-03-01 | reit | HC Wainwright & Co. | Buy → Buy | $45 |
- TG Therapeutics, Inc. (TGTX) Stock Analysis: A 50% Upside Potential In Biotech - DirectorsTalk Interviews Mon, 23 Feb 2026 19
- TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q4 Release - Yahoo Finance Mon, 23 Feb 2026 15
- Five Year BRIUMVI Data Shapes TG Therapeutics Risk Reward Profile - simplywall.st ue, 24 Feb 2026 16
- TG Therapeutics: What Wall Street Isn't Telling You (NASDAQ:TGTX) - Seeking Alpha ue, 30 Dec 2025 08
- 5-year MS study: BRIUMVI patients average one relapse every 50 years - Stock Titan ue, 17 Feb 2026 12
- The Earnings Caveat That Sent This Hot Biotech Diving - Investor's Business Daily Mon, 03 Nov 2025 08
- TG Therapeutics (TGTX) stock drops 7% as JPMorgan healthcare conference nears — what investors watch next - TechStock² Fri, 09 Jan 2026 08
- TG Therapeutics, Inc. (NASDAQ:TGTX) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? - Yahoo Finance Fri, 31 Oct 2025 07
- TG Therapeutics, Inc. (TGTX) Stock Analysis: A 55.89% Potential Upside in the Biotech Space - DirectorsTalk Interviews Mon, 16 Feb 2026 08
- Christina Applegate fronts new MS honesty campaign with TG Therapeutics - Stock Titan Sun, 08 Feb 2026 08
- Assessing TG Therapeutics (TGTX) Valuation After Long Term BRIUMVI Multiple Sclerosis Data Release - simplywall.st hu, 19 Feb 2026 19
- TG Therapeutics: The 'Exit Velocity' You Can't Ignore (Rating Upgrade) - Seeking Alpha hu, 15 Jan 2026 08
- Real-world and pediatric MS data put BRIUMVI under spotlight at ACTRIMS - Stock Titan Fri, 06 Feb 2026 08
- TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q3 Release - Yahoo Finance Mon, 27 Oct 2025 07
- Deloitte Fast 500 names TG Therapeutics (NASDAQ: TGTX) among North America’s fastest-growing firms - Stock Titan Wed, 19 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 43197 | — | — | Stock Gift at price 0.00 per share. | CHARNEY LAURENCE NEIL | Director | — | 2026-01-29 00:00:00 | D |
| 1 | 90000 | — | — | Stock Award(Grant) at price 0.00 per share. | POWER SEAN A | Chief Financial Officer | — | 2026-01-08 00:00:00 | D |
| 2 | 622000 | — | — | Stock Award(Grant) at price 0.00 per share. | WEISS MICHAEL S | Chief Executive Officer | — | 2026-01-08 00:00:00 | D |
| 3 | 5000 | 162850 | — | Sale at price 32.57 per share. | ECHELARD YANN | Director | — | 2025-11-24 00:00:00 | D |
| 4 | 4668843 | — | — | Stock Gift at price 0.00 per share. | WEISS MICHAEL S | Chief Executive Officer | — | 2025-11-05 00:00:00 | D |
| 5 | 20852 | 672268 | — | Sale at price 32.24 per share. | LONIAL SAGAR | Director | — | 2025-09-11 00:00:00 | D |
| 6 | 10000 | 369400 | — | Sale at price 36.94 per share. | ECHELARD YANN | Director | — | 2025-06-13 00:00:00 | D |
| 7 | 14718 | — | — | Stock Award(Grant) at price 0.00 per share. | ECHELARD YANN | Director | — | 2025-06-12 00:00:00 | D |
| 8 | 14718 | — | — | Stock Award(Grant) at price 0.00 per share. | HOBERMAN KENNETH | Director | — | 2025-06-12 00:00:00 | D |
| 9 | 14718 | — | — | Stock Award(Grant) at price 0.00 per share. | HUME DANIEL | Director | — | 2025-06-12 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.09 | 0.03 | 0.00 | 0.00 |
| NormalizedEBITDA | 49.90M | 26.10M | -213.11M | -341.97M |
| NetIncomeFromContinuingOperationNetMinorityInterest | 23.38M | 12.67M | -223.81M | -348.10M |
| ReconciledDepreciation | 280.00K | 423.00K | 515.00K | 494.00K |
| ReconciledCostOfRevenue | 38.49M | 14.13M | 265.00K | 790.00K |
| EBITDA | 49.90M | 26.10M | -213.11M | -341.97M |
| EBIT | 49.62M | 25.68M | -213.62M | -342.46M |
| NetInterestIncome | -24.03M | -12.62M | -10.19M | -5.64M |
| InterestExpense | 24.03M | 12.62M | 10.19M | 5.64M |
| NormalizedIncome | 23.38M | 12.67M | -223.81M | -348.10M |
| NetIncomeFromContinuingAndDiscontinuedOperation | 23.38M | 12.67M | -223.81M | -348.10M |
| TotalExpenses | 287.07M | 213.03M | 221.10M | 351.46M |
| TotalOperatingIncomeAsReported | 41.93M | 20.63M | -218.32M | -344.77M |
| DilutedAverageShares | 160.34M | 148.51M | 135.41M | 132.22M |
| BasicAverageShares | 145.32M | 141.96M | 135.41M | 132.22M |
| DilutedEPS | 0.15 | 0.09 | -1.46 | -2.63 |
| BasicEPS | 0.16 | 0.09 | -1.46 | -2.63 |
| DilutedNIAvailtoComStockholders | 23.38M | 12.67M | -223.81M | -348.10M |
| NetIncomeCommonStockholders | 23.38M | 12.67M | -223.81M | -348.10M |
| NetIncome | 23.38M | 12.67M | -223.81M | -348.10M |
| NetIncomeIncludingNoncontrollingInterests | 23.38M | 12.67M | -223.81M | -348.10M |
| NetIncomeContinuousOperations | 23.38M | 12.67M | -223.81M | -348.10M |
| TaxProvision | 2.21M | 390.00K | 0.00 | 0.00 |
| PretaxIncome | 25.59M | 13.06M | -223.81M | -348.10M |
| OtherIncomeExpense | 7.69M | 5.04M | 4.70M | 2.31M |
| OtherNonOperatingIncomeExpenses | 7.69M | 5.04M | 4.70M | 2.31M |
| NetNonOperatingInterestIncomeExpense | -24.03M | -12.62M | -10.19M | -5.64M |
| InterestExpenseNonOperating | 24.03M | 12.62M | 10.19M | 5.64M |
| OperatingIncome | 41.93M | 20.63M | -218.32M | -344.77M |
| OperatingExpense | 248.59M | 198.90M | 220.84M | 350.67M |
| ResearchAndDevelopment | 94.29M | 76.19M | 125.35M | 222.58M |
| SellingGeneralAndAdministration | 154.30M | 122.71M | 95.48M | 128.09M |
| SellingAndMarketingExpense | 64.05M | 90.86M | ||
| GeneralAndAdministrativeExpense | 154.30M | 122.71M | 95.48M | 128.09M |
| OtherGandA | 122.92M | 97.78M | 64.05M | 90.86M |
| SalariesAndWages | 31.38M | 24.92M | 31.44M | 37.23M |
| GrossProfit | 290.52M | 219.53M | 2.52M | 5.90M |
| CostOfRevenue | 38.49M | 14.13M | 265.00K | 790.00K |
| TotalRevenue | 329.00M | 233.66M | 2.79M | 6.69M |
| OperatingRevenue | 329.00M | 233.66M | 2.79M | 6.69M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 367.90K | 41.31K | 41.31K | 41.31K |
| OrdinarySharesNumber | 155.84M | 151.42M | 146.39M | 143.25M |
| ShareIssued | 156.20M | 151.47M | 146.43M | 143.29M |
| NetDebt | 64.53M | 7.18M | ||
| TotalDebt | 253.72M | 110.80M | 83.06M | 79.05M |
| TangibleBookValue | 222.36M | 160.50M | 57.79M | 236.35M |
| InvestedCapital | 466.79M | 260.62M | 129.72M | 304.92M |
| WorkingCapital | 475.68M | 264.22M | 115.07M | 265.58M |
| NetTangibleAssets | 222.36M | 160.50M | 57.79M | 236.35M |
| CapitalLeaseObligations | 9.29M | 10.68M | 11.93M | 11.28M |
| CommonStockEquity | 222.36M | 160.50M | 58.59M | 237.15M |
| TotalCapitalization | 466.79M | 260.62M | 129.72M | 303.94M |
| TotalEquityGrossMinorityInterest | 222.36M | 160.50M | 58.59M | 237.15M |
| StockholdersEquity | 222.36M | 160.50M | 58.59M | 237.15M |
| TreasuryStock | 8.99M | 234.00K | 234.00K | 234.00K |
| RetainedEarnings | -1.53B | -1.55B | -1.53B | -1.33B |
| AdditionalPaidInCapital | 1.76B | 1.71B | 1.59B | 1.57B |
| CapitalStock | 156.00K | 151.00K | 146.00K | 143.00K |
| CommonStock | 156.00K | 151.00K | 146.00K | 143.00K |
| TotalLiabilitiesNetMinorityInterest | 355.33M | 169.09M | 134.99M | 142.48M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 264.65M | 115.36M | 81.78M | 77.09M |
| NonCurrentDeferredLiabilities | 12.09M | 6.02M | 305.00K | 457.00K |
| NonCurrentDeferredRevenue | 12.09M | 6.02M | 305.00K | 457.00K |
| LongTermDebtAndCapitalLeaseObligation | 252.56M | 109.35M | 81.48M | 76.64M |
| LongTermCapitalLeaseObligation | 8.13M | 9.23M | 10.34M | 9.85M |
| LongTermDebt | 244.43M | 100.12M | 71.14M | 66.79M |
| CurrentLiabilities | 90.68M | 53.72M | 53.20M | 65.38M |
| OtherCurrentLiabilities | 4.63M | 1.48M | 1.17M | 1.51M |
| CurrentDeferredLiabilities | 11.41M | 152.00K | ||
| CurrentDeferredRevenue | 11.41M | 152.00K | ||
| CurrentDebtAndCapitalLeaseObligation | 1.16M | 1.45M | 1.58M | 2.41M |
| CurrentCapitalLeaseObligation | 1.16M | 1.45M | 1.58M | 1.44M |
| CurrentDebt | 975.00K | |||
| OtherCurrentBorrowings | 975.00K | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 15.19M | 12.17M | 8.43M | 10.17M |
| PayablesAndAccruedExpenses | 58.30M | 38.47M | 42.02M | 51.29M |
| TotalAssets | 577.69M | 329.59M | 193.57M | 379.63M |
| TotalNonCurrentAssets | 11.33M | 11.64M | 25.30M | 48.66M |
| OtherNonCurrentAssets | 3.37M | 3.59M | 1.27M | 1.26M |
| InvestmentsAndAdvances | 808.00K | 0.00 | 12.40M | 35.53M |
| InvestmentinFinancialAssets | 808.00K | 0.00 | 12.40M | 35.53M |
| HeldToMaturitySecurities | 808.00K | 0.00 | 12.40M | 35.53M |
| GoodwillAndOtherIntangibleAssets | 799.00K | 799.00K | 799.00K | |
| Goodwill | 799.00K | 799.00K | 799.00K | |
| NetPPE | 7.15M | 8.05M | 10.82M | 11.07M |
| GrossPPE | 7.15M | 8.05M | 10.82M | 11.07M |
| Leases | 1.42M | 1.63M | 1.84M | |
| OtherProperties | 7.15M | 8.05M | 9.20M | 9.23M |
| Properties | 0.00 | 0.00 | 0.00 | |
| CurrentAssets | 566.36M | 317.94M | 168.27M | 330.96M |
| OtherCurrentAssets | 15.72M | 9.52M | 2.36M | 2.88M |
| PrepaidAssets | 4.18M | 4.24M | 11.93M | |
| Inventory | 110.46M | 39.82M | 0.00 | |
| Receivables | 129.19M | 51.09M | 0.00 | 1.39M |
| AccountsReceivable | 129.19M | 51.09M | 0.00 | 1.39M |
| CashCashEquivalentsAndShortTermInvestments | 311.00M | 217.51M | 161.68M | 314.76M |
| OtherShortTermInvestments | 131.11M | 124.58M | 59.37M | 15.88M |
| CashAndCashEquivalents | 179.89M | 92.93M | 102.30M | 298.89M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -40.56M | -31.41M | -176.18M | -296.04M |
| RepurchaseOfCapitalStock | -8.76M | 0.00 | 0.00 | |
| RepaymentOfDebt | -107.55M | 0.00 | -975.00K | -30.00M |
| IssuanceOfDebt | 244.81M | 25.00M | 0.00 | 70.00M |
| IssuanceOfCapitalStock | 46.30M | 0.00 | 2.22M | |
| CapitalExpenditure | -45.00K | -14.00K | -401.00K | |
| InterestPaidSupplementalData | 18.47M | 8.77M | 5.45M | 3.47M |
| IncomeTaxPaidSupplementalData | 500.00K | 0.00 | 0.00 | |
| EndCashPosition | 181.19M | 94.22M | 103.58M | 300.15M |
| BeginningCashPosition | 94.22M | 103.58M | 300.15M | 554.70M |
| ChangesInCash | 86.97M | -9.36M | -196.57M | -254.55M |
| FinancingCashFlow | 128.53M | 72.70M | -391.00K | 41.42M |
| CashFlowFromContinuingFinancingActivities | 128.53M | 72.70M | -391.00K | 41.42M |
| NetOtherFinancingCharges | -889.00K | -125.00K | -1.02M | |
| InterestPaidCFF | -1.02M | |||
| ProceedsFromStockOptionExercised | 914.00K | 1.53M | 584.00K | 216.00K |
| CashDividendsPaid | 0.00 | |||
| NetCommonStockIssuance | -8.76M | 46.30M | 0.00 | 2.22M |
| CommonStockPayments | -8.76M | 0.00 | 0.00 | |
| CommonStockIssuance | 46.30M | 0.00 | 2.22M | |
| NetIssuancePaymentsOfDebt | 137.26M | 25.00M | -975.00K | 40.00M |
| NetLongTermDebtIssuance | 137.26M | 25.00M | -975.00K | 40.00M |
| LongTermDebtPayments | -107.55M | 0.00 | -975.00K | -30.00M |
| LongTermDebtIssuance | 244.81M | 25.00M | 0.00 | 70.00M |
| InvestingCashFlow | -1.04M | -50.65M | -20.01M | -332.00K |
| CashFlowFromContinuingInvestingActivities | -1.04M | -50.65M | -20.01M | -332.00K |
| NetInvestmentPurchaseAndSale | -991.00K | -50.65M | -20.00M | 69.00K |
| SaleOfInvestment | 310.90M | 96.23M | 87.28M | 55.60M |
| PurchaseOfInvestment | -311.89M | -146.88M | -107.27M | -55.53M |
| NetPPEPurchaseAndSale | -45.00K | 0.00 | -14.00K | -401.00K |
| PurchaseOfPPE | -45.00K | 0.00 | -14.00K | -401.00K |
| OperatingCashFlow | -40.52M | -31.41M | -176.17M | -295.63M |
| CashFlowFromContinuingOperatingActivities | -40.52M | -31.41M | -176.17M | -295.63M |
| ChangeInWorkingCapital | -109.30M | -84.66M | -1.65M | -12.22M |
| ChangeInOtherWorkingCapital | 17.48M | 5.71M | -152.00K | -152.00K |
| ChangeInOtherCurrentLiabilities | 1.64M | 300.00K | -55.00K | -18.16M |
| ChangeInOtherCurrentAssets | -6.32M | -2.83M | 8.18M | -8.51M |
| ChangeInPayablesAndAccruedExpense | 22.84M | 192.00K | -11.01M | 15.99M |
| ChangeInInventory | -66.85M | -36.94M | 0.00 | 0.00 |
| ChangeInReceivables | -78.09M | -51.09M | 1.39M | -1.39M |
| ChangesInAccountReceivables | -78.09M | -51.09M | 1.39M | -1.39M |
| OtherNonCashItems | 4.20M | 4.45M | 4.44M | 2.40M |
| StockBasedCompensation | 42.54M | 37.93M | 44.66M | 61.27M |
| UnrealizedGainLossOnInvestmentSecurities | 754.00K | 0.00 | 0.00 | |
| AmortizationOfSecurities | -6.98M | -2.24M | -331.00K | 517.00K |
| DepreciationAmortizationDepletion | 280.00K | 423.00K | 515.00K | 494.00K |
| DepreciationAndAmortization | 280.00K | 423.00K | 515.00K | 494.00K |
| Depreciation | 280.00K | 423.00K | 515.00K | 494.00K |
| OperatingGainsLosses | 4.61M | |||
| NetIncomeFromContinuingOperations | 23.38M | 12.67M | -223.81M | -348.10M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for TGTX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|